Genitourinary Cancer

This is the time of year when I often reflect on progress in the area of my greatest clinical interest, genitourinary oncology.

Oncologists acted promptly in response to an FDA restriction last year on the label indication for two immunotherapies, effectively reducing their use by about 50% within 6 months, according to results of a study published in JAMA.

A shortage of the chemotherapy drug vincristine, which is essential to the treatment of most pediatric cancers, has left the oncology community struggling to find short-term solutions while recognizing the need for long-term reform.

In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the most exciting developments in renal cell carcinoma in the past year.